|9.43||+0.2100||+2.28%||Vol 767||1Y Perf 58.32%|
|Apr 9th, 2021 13:42 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★ 56.86|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★★★★★ 78.24|
|Market Cap||-||Earnings Rating||—|
|Price Range Ratio 52W %||98.72||Earnings Date||-|
Today's Price Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||723|
|Avg. Monthly Volume||521|
|Avg. Quarterly Volume||574|
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock (NASDAQ: CYCCP) stock closed at 9.43 per share at the end of the most recent trading day (a 2.28% change compared to the prior day closing price) with a volume of 767.0000 shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock CEO is Spiro Rombotis.
The one-year performance of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is 58.32%, while year-to-date (YTD) performance is 34.14%. CYCCP stock has a five-year performance of 109.56%. Its 52-week range is between 4.81 and 9.49, which gives CYCCP stock a 52-week price range ratio of 98.72%
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 13.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.46%, a ROC of -40.58% and a ROE of -54.02%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a dividend yield of 6.85% with a dividend per share of $0.60 and a payout ratio of -%.
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock has a Buy technical analysis rating based on Technical Indicators (ADX : 13.30, ATR14 : 0.48, CCI20 : -29.80, Chaikin Money Flow : 0.04, MACD : -0.25, Money Flow Index : 12.90, ROC : 1.36, RSI : 37.94, STOCH (14,3) : 15.38, STOCH RSI : 0.00, UO : 8.82, Williams %R : -84.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock in the last 12-months were:
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.